Genetic risk factor of COPD
Even if an individual has never smoked or been unprotected to pollutants for an extended period, they can still develop COPD. Alpha-1 Antitrypsin Deficiency (AATD) is the most commonly known genetic risk factor of COPD in emphysema. Alpha-1 Antitrypsin related COPD is caused by a deficiency of the Alpha-1 in the bloodstream. Without the Alpha-1 Antitrypsin protein, white blood cells begin to harm the lungs and lung deterioration occurs. The World Health Organization and the American Thoracic Society suggests that everyone determined to have COPD be tested for Alpha-1.
Related Conference of Genetic risk factor of COPD
October 22-23, 2025
5th International Conference on Tuberculosis, Lung Health and Respiratory Diseases
Paris, France
November 24-25, 2025
17th International Conference on Chronic Obstructive Pulmonary Disease
Barcelona, Spain
Genetic risk factor of COPD Conference Speakers
Recommended Sessions
- Asthma
- Chronic Obstructive Pulmonary Disease
- Alpha 1 Antitrypsin Deficiency & COPD
- Cardiopulmonary Disorders
- Clinical management of severe acute respiratory infection
- COVID-19 Treatment and Recovery
- Covid19 Vaccine and Lung Immunopathology
- Cystic Fibrosis
- Depression and anxiety in COPD
- Diagnosis and Treatment of COPD
- Digital Health in Respiratory Care
- Effect of COVID-19 on Lungs
- Genetic risk factor of COPD
- Idiopathic Pulmonary Fibrosis
- Innate Immunity and Lung Fibrosis
- Investigational Drugs and Other Therapies in the treatment of Respiratory Disease
- Lung cancer
- Lung Cancer Diagnosis & Treatment
- Pathology and Clinical Management of COPD
- Pneumonia
- Pulmonary Rehabilitation
- Respiratory Diseases
- Severe Acute Respiratory Syndrome (SARS)
- Sleep apnea
- Tuberculosis
Related Journals
Are you interested in
- Advances in Tuberculosis Diagnosis, Treatment, and Prevention - Tuberculosis-2025 (France)
- Asthma - Pulmonary Meet 2025 (France)
- Asthma and COPD - COPD_2025 (Spain)
- Chronic Bronchitis - Pulmonary Meet 2025 (France)
- Chronic Obstructive Pulmonary Disease - COPD_2025 (Spain)
- Co-Morbidities of COPD - COPD_2025 (Spain)
- Community-based Approaches to TB and Lung Health Awareness - Tuberculosis-2025 (France)
- COPD - Pulmonary Meet 2025 (France)
- COPD and Cardiovascular Diseases - COPD_2025 (Spain)
- COPD Complications - COPD_2025 (Spain)
- COPD Exacerbations - COPD_2025 (Spain)
- COPD Pathogenesis - COPD_2025 (Spain)
- COPD Therapeutics - COPD_2025 (Spain)
- COPD: Sign and Symptoms - COPD_2025 (Spain)
- Cystic Fibrosis - Pulmonary Meet 2025 (France)
- Depression and anxiety in COPD - COPD_2025 (Spain)
- Digital Health Technologies for Respiratory Disease Management - Tuberculosis-2025 (France)
- Drug Discovery of COPD - COPD_2025 (Spain)
- Early Diagnosis and Biomarkers in Respiratory Diseases - Tuberculosis-2025 (France)
- Emerging Respiratory Threats and Pandemic Preparedness - Tuberculosis-2025 (France)
- Emphysema - Pulmonary Meet 2025 (France)
- Epidemiology of COPD - COPD_2025 (Spain)
- Genetic risk factor of COPD - COPD_2025 (Spain)
- Genetics and Susceptibility to Tuberculosis and Lung Diseases - Tuberculosis-2025 (France)
- Global Efforts to Eliminate Tuberculosis by 2030 - Tuberculosis-2025 (France)
- Hospital-acquired Infections and Respiratory Care - Tuberculosis-2025 (France)
- Impact of Smoking and Environmental Factors on Lung Health - Tuberculosis-2025 (France)
- Infectious Respiratory Diseases - Pulmonary Meet 2025 (France)
- Interstitial lung disease - Pulmonary Meet 2025 (France)
- Latent Tuberculosis: Diagnosis, Treatment, and Control - Tuberculosis-2025 (France)
- Lung cancer - COPD_2025 (Spain)
- Lung Cancer - Pulmonary Meet 2025 (France)
- Lung Health: Emerging Trends and Challenges - Tuberculosis-2025 (France)
- Lung problems - Pulmonary Meet 2025 (France)
- Lung transplantation - Pulmonary Meet 2025 (France)
- Multidrug-Resistant Tuberculosis (MDR-TB) and Novel Therapies - Tuberculosis-2025 (France)
- Neonatal and Maternal Respiratory Health - Tuberculosis-2025 (France)
- Novel Therapies and Drug Development for Tuberculosis - Tuberculosis-2025 (France)
- Pathophysiology of COPD - COPD_2025 (Spain)
- Pediatric Pulmonary, Critical care and Sleep - COPD_2025 (Spain)
- Pediatric Tuberculosis and Respiratory Health - Tuberculosis-2025 (France)
- Pleural Diseases - Pulmonary Meet 2025 (France)
- Prevention and Control of Respiratory disease - Pulmonary Meet 2025 (France)
- Pulmonary diseases-treatment and therapies - COPD_2025 (Spain)
- Pulmonary Hypertension - Pulmonary Meet 2025 (France)
- Pulmonary Hypertension - COPD_2025 (Spain)
- Pulmonary Rehabilitation - Pulmonary Meet 2025 (France)
- Pulmonary Rehabilitation and Holistic Care for Respiratory Diseases - Tuberculosis-2025 (France)
- Pulmonary vascular disease - Pulmonary Meet 2025 (France)
- Pulmonology - Pulmonary Meet 2025 (France)
- Respiratory Disorders - Pulmonary Meet 2025 (France)
- Respiratory Infections and Global Public Health Concerns - Tuberculosis-2025 (France)
- Respiratory Infections and Global Public Health Concerns - Tuberculosis-2025 (France)
- Respiratory Tract Infections - Pulmonary Meet 2025 (France)
- Role of Artificial Intelligence in Tuberculosis Diagnosis - Tuberculosis-2025 (France)
- Self-Management and Prevention of COPD - COPD_2025 (Spain)
- Sleep-Related Respiratory Disorders - Pulmonary Meet 2025 (France)
- Tuberculosis - Pulmonary Meet 2025 (France)
- Tuberculosis and HIV Co-infection: Challenges and Treatment - Tuberculosis-2025 (France)
- Tuberculosis Prevention and Global Public Health Strategies - Tuberculosis-2025 (France)
- Types of COPD - COPD_2025 (Spain)